Advertisement

Neurofeedback for Autistic Spectrum Disorder: A Review of the Literature

  • Robert Coben
  • Michael Linden
  • Thomas E. Myers
Article

Abstract

There is a need for effective interventions to address the core symptoms and problems associated with autistic spectrum disorder (ASD). Behavior therapy improves communication and behavioral functioning. Additional treatment options include psychopharmacological and biomedical interventions. Although these approaches help children with autistic problems, they may be associated with side effects, risks or require ongoing or long-term treatment. Neurofeedback is a noninvasive approach shown to enhance neuroregulation and metabolic function in ASD. We present a review of the literature on the application of Neurofeedback to the multiple problems associated with ASD. Directions for future research are discussed.

Keywords

Autistic spectrum disorder Treatment Neurofeedback 

References

  1. Adams, J., Geis, L., Baral, M., Mitchell, J. I., Hensley, A., Newmark, S., et al. (2008). Results of DMSA treatment study. Presented at the Autism One Conference, Chicago, Illinois.Google Scholar
  2. Aman, M. G., Singh, N. N., & Stewart, A. W. (1985). The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491.Google Scholar
  3. American Academy of Child & Adolescent Psychiatry. (1999, March 3). Secretin in the treatment of autism [Policy statement]. Retrieved August 6, 2007 from http://www.aacap.org/cs/root/policy_statements/secretin_in_the_treatment_of_autism.
  4. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders, fourth edition-text revision. Washington, DC: American Psychiatric Association.Google Scholar
  5. Amminger, G. P., Berger, G. E., Schafer, M. R., Klier, C., Friedrich, M. H., & Feucht, M. (2007). Omega-3 fatty acids supplementation in children with autism: A double-blind randomized, placebo-controlled study. Biological Psychiatry, 61, 551–553.PubMedGoogle Scholar
  6. Anderson, S. R., Avery, D. L., DiPietro, E. K., Edwards, G. L., & Christian, W. P. (1987). Intensive home-based early intervention with autistic children. Education and Treatment of Children, 10, 352–366.Google Scholar
  7. Association for Applied Psychophysiology & Biofeedback. (2006). Efficacy: How we rate the efficacy of our treatments or how to know if our treatments actually work. Retrieved February 22, 2006 from http://www.aapb.org/i4a/pages/index.cfm?pageid=3336.
  8. Attwood, T. (1998). Asperger’s syndrome: A guide for parents and professionals. London, England: Jessica Kingsley Publishers.Google Scholar
  9. Barnard, A. L., Young, A. H., Pearson, A. D. J., Geddes, J., & Obrien, G. (2002). A systematic review of the use of atypical antipsychotics in autism. Journal of Psychopharmacology, 16, 93–102.PubMedGoogle Scholar
  10. Bassett, K., Green, C. J., & Kazanjian, A. (2000). Autism and Lovaas treatment: A systematic review of effectiveness evidence. Vancouver, BC: British Columbia Office of Health Technology Assessment, The University of British Columbia.Google Scholar
  11. Bayley, N. (1993). Bayley scales of infant development (2nd ed.). San Antonio: Psychological Corp.Google Scholar
  12. Bell, J. G., Sargent, J. R., Tocher, D. R., & Dick, J. R. (2000). Red blood cell fatty acid compositions in a patient with autistic spectrum disorder: A characteristic abnormality in neurodevelopmental disorders? Prostaglandins, Leukotienes and Essential Fatty Acids, 63(1–2), 21–25.Google Scholar
  13. Ben-Itzchak, E., & Zachor, D. A. (2007). The effects of intellectual functioning and autism severity on outcome of early intervention for children with autism. Research in Developmental Disabilities, 28, 287–303.PubMedGoogle Scholar
  14. Bernard, S., Enayati, A., Binstock, T., Roger, H., Redwood, L., & McGinnis, W. (2000) Autism: A unique type of mercury poisoning. ARC Research, Available from the Autism Research Institute.Google Scholar
  15. Birnbrauer, J. S., & Leach, D. J. (1993). The Murdoch early intervention program after 2 years. Behavior Change, 10, 63–74.Google Scholar
  16. Blaxill, M. F. (2004). What’s going on? The question of time trends in autism. Public Health Reports, 119, 536–551.PubMedGoogle Scholar
  17. Bradstreet, J., Geier, B. A., Kartzinel, J. J., Adams, J. B., & Geier, M. R. (2003). A case–control study of mercury burden in children with autistic spectrum disorders. Journal of American Physicians and Surgeons, 8(3), 76–79.Google Scholar
  18. Butter, E. M., Mulick, J. A., & Metz, B. (2006). Eight case reports of learning recovery in children with pervasive developmental disorders after early intervention. Behavioral Interventions, 21, 227–243.Google Scholar
  19. Cade, R., Privette, M., Fregley, M., Rowland, N., Sun, Z., Zele, V., et al. (1999). Autism and schizophrenia: Intestinal disorders. Nutritional Neuroscience, 3, 57–72.Google Scholar
  20. Carmen, J. A. (2004). Passive infared hemoencephalography: Four years and 100 migraines. Journal of Neurotherapy, 8(3), 23–51.Google Scholar
  21. Center for Disease Control and Prevention. (2006). How common are autism spectrum disorder (ASD)? Retrieved May 31, 2006 from http://www.cdc.gov/ncbddd/autism/asd_common.htm.
  22. Center for Disease Control and Prevention. (2007). Prevalence of the autism spectrum disorders (ASDs in Multiple Areas of the United States, 2000 and 2002). MMWR, 56 (SS 1–2).Google Scholar
  23. Coben, R. (2006, September). Hemoencephalography for autistic spectrum disorder. Presented at the 14th Annual Conference of the International Society for Neuronal Regulation, Atlanta, Georgia.Google Scholar
  24. Coben, R. (2007, September). Autistic spectrum disorder: A controlled study of EEG coherence training targeting social skill deficits. Presented at the 15th annual conference of the International Society for Neurofeedback and Research, San Diego, California.Google Scholar
  25. Coben, R. (2009). Efficacy of connectivity guided neurofeedback for autistic spectrum disorder: Controlled analysis of 75 cases with a 1 to 2 year follow-up. Journal of Neurotherapy, 13(1), 81.Google Scholar
  26. Coben, R., Hirshberg, L. M., & Chabot, R. (Under Review). EEG discriminant power and subtypes in autistic spectrum disorder. International Journal of Psychophysiology. Google Scholar
  27. Coben, R., & Hudspeth, W. (2006, September). Mu-like rhythms in autistic spectrum disorder: EEG analyses and neurofeedback. Presented at the 14th Annual Conference of the International Society for Neuronal Regulation, Atlanta, Georgia.Google Scholar
  28. Coben, R., & Myers, T. E. (2008). Connectivity theory of autism: Use of connectivity measures in assessing and treating autistic disorders. Journal of Neurotherapy, 12(2–3), 161–179.Google Scholar
  29. Coben, R. & Myers, T. E. (2009). The relative efficacy of connectivity guided and symptom based EEG biofeedback for Autistic disorders. Applied Psychophysiology and Biofeedback. doi: 10.1007/s10484-009-9102-5.
  30. Coben, R., & Padolsky, I. (2007). Assessment-guided neurofeedback for autistic spectrum disorder. Journal of Neurotherapy, 11(3), 5–18.Google Scholar
  31. Committee on Children with Disabilities. (2001). Technical report: The pediatrician’s role in the diagnosis and management of autistic spectrum disorder in children. Pediatrics, 107(5), 1–35.Google Scholar
  32. Cook, E. H., Rowlett, R., & Jaselskis, C. (1992). Fluoxetine treatment of children and adults with autistic disorder and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 739–745.PubMedGoogle Scholar
  33. Couper, J. (2004). Who should pay for intensive behavioural intervention in autism? A parent’s view. Journal of Paediatrics and Child Health, 40(9–10), 559–561.PubMedGoogle Scholar
  34. Couturier, J. L., & Nicolson, R. (2002). A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 12, 243–248.PubMedGoogle Scholar
  35. Cowan, J., & Markham, L. (1994, March). EEG biofeedback for the attention problems of autism: A case study. Presented at the 25th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, Atlanta, GA.Google Scholar
  36. DeLong, G. R., Ritch, C. R., & Burch, S. (2002). Fluoxetine response in children with autistic spectrum disorders: Correlation with familial major affective disorder and intellectual achievement. Developmental Medicine and Child Neurology, 44, 652–659.PubMedGoogle Scholar
  37. Demos, J. N. (2005). Getting started with neurofeedback. New York: WW Norton & Company.Google Scholar
  38. Deprey, L. J., Brule, N., Widjaja, F., Sepheri, S., Blank, J., Neubrander, J., et al. (2006, October). Double-blind placebo-controlled, cross-over trial of subcutaneous methylcobalamin in children with autism: Preliminary results. Poster presented at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Diego, CA.Google Scholar
  39. Deth, R. C. (2004, October) Methylcobalamin for autistic children. Presented at the 34th Annual Meeting of the Society for Neuroscience, San Diego, CA.Google Scholar
  40. Dietrich, K. N., Ware, J. H., Salganik, M., Radcliffe, J., Rogan, W. J., Rhoads, G. G., et al. (2004). Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. Pediatrics, 114, 19–26.PubMedGoogle Scholar
  41. Ducharme, J. M. (2005). Errorless compliance training. In M. Hersen & J. Rosqvist (Eds.), Encyclopedia of behavior modification and cognitive behavior therapy (Vol. 2: Child Clinical Applications). Thousand Oaks, CA: Sage.Google Scholar
  42. Ducharme, J. M., Sanjuan, E., & Drain, T. (2007). Errorless compliance training. Success-focused behavioral treatment of children with Asperger syndrome. Behavior Modification, 31, 329–344.PubMedGoogle Scholar
  43. Egner, T., & Sterman, M. B. (2006). Neurofeedback treatment of epilepsy: From basic rationale to practical application. Expert Review of Neurotherapeutics, 6, 247–257.PubMedGoogle Scholar
  44. Eikeseth, S., Smith, T., Jahr, E., & Eldevik, S. (2002). Intensive behavioral treatment at school for 4–7-year-old children with autism: A 1-year comparison controlled study. Behavior Modification, 26, 49–68.PubMedGoogle Scholar
  45. Eikeseth, S., Smith, T., Jahr, E., & Eldevik, S. (2007). Outcome for children with autism who began intensive behavioral treatment between ages 4 and 7: A comparison controlled study. Behavior Modification, 31, 264–278.PubMedGoogle Scholar
  46. Elder, J. H., Shankar, M., Shuster, J., Theriaque, D., Burns, S., & Sherrill, L. (2006). The gluten-free, casein-free diet in autism: Results of a preliminary double blind clinical trial. Journal of Autism and Developmental Disorders, 36, 413–420.PubMedGoogle Scholar
  47. Esch, B. E., & Carr, J. E. (2004). Secretin as a treatment for autism: A review of the evidence. Journal of Autism and Developmental Disorders, 34, 543–556.PubMedGoogle Scholar
  48. Fenske, E. C., Zalenski, S., Krantz, P. J., & McClannahan, L. E. (1985). Age at intervention and treatment outcome for autistic children in a comprehensive intervention program. Analysis and Intervention in Developmental Disabilities, 5, 49–58.Google Scholar
  49. Fuchs, T., Birbaumer, N., Lutzenberger, W., Gruzelier, J. H., & Kaiser, J. (2003). Neurofeedback treatment for attention-deficit/hyperactivity disorder in children: A comparison with methylphenidate. Applied Psychophysiology and Biofeedback, 28, 1–12.PubMedGoogle Scholar
  50. Geller, D. A., Hoog, S. L., Heiligenstein, J. H., Ricardi, R. K., Tamura, R., Kluszynski, S., et al. (2001). Fluoxetine treatment for obsessive compulsive disorder in children and adolescents: A placebo controlled clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 40(7), 773–779.PubMedGoogle Scholar
  51. George, M. S., Costa, D. C., Kouris, K., Ring, H. A., & Ell, P. J. (1992). Cerebral blood flow abnormalities in adults with infantile autism. Journal of Nervous and Mental Disease, 180, 413–417.PubMedGoogle Scholar
  52. Golden, Z. L., Neubauer, R., Golden, C. J., Greene, L., Marsh, J., & Mleko, A. (2002). Improvement in cerebral metabolism in chronic brain injury after hyperbaric oxygen therapy. International Journal of Neuroscience, 112, 119–131.PubMedGoogle Scholar
  53. Green, V. A., Pituch, K. A., Itchon, J., Choi, A., O’Reilly, M., & Sigafoos, J. (2006). Internet survey of treatments used by parents of children with autism. Research in Developmental Disabilities, 27, 70–84.PubMedGoogle Scholar
  54. Hamilton, L. (2000). Facing autism: Giving parents reasons for hope and guidance for help. Colorado Springs, Colorado: Water Brook Press.Google Scholar
  55. Hammond, D. C. (2005). What is neurofeedback? Retrieved July 25, 2006 from http://www.isnr.org/pubarea/whatisnfb.pdf.
  56. Harris, S. L., Handleman, J. S., Gordon, R., Kristoff, B., & Fuentes, F. (1991). Changes in cognitive and language functioning of preschool children with autism. Journal of Autism and Developmental Disorders, 21, 281–290.PubMedGoogle Scholar
  57. Hediger, M. L., England, L. J., Molloy, C. A., Yu, K. F., Manning-Courtney, P., & Mills, J. L. (2008). Reduced bone cortical thickness in boys with autism or autism spectrum disorder. Journal of Autism and Developmental Disorders, 38, 848–856.PubMedGoogle Scholar
  58. Hellings, J. A., Kelley, L. A., Gabrielli, W. F., Kilgore, E., & Shah, P. (1996). Sertraline response in adults with mental retardation and autistic disorder. Journal of Clinical Psychiatry, 57, 333–336.PubMedGoogle Scholar
  59. Herbert, J. D., Sharp, I. R., & Gaudiano, B. A. (2002). Separating fact from fiction in the etiology and treatment of autism. A scientific review of the evidence. The Scientific Review of Mental Health Practice, 1(1). Accessed online at: http://www.srmhp.org/0101/autism.html.
  60. Hill, E. L. (2004). Executive dysfunction in autism. Trends in Cognitive Sciences, 8(1), 26–32.PubMedGoogle Scholar
  61. Hirsch, D. (1999). Secretin in the treatment of autism. The Exceptional Parent, 29, 94.Google Scholar
  62. Hollander, E., Phillips, A., Chaplin, W., Zagursky, K., Novotny, S., Wasserman, S., et al. (2005). A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30, 582–589.PubMedGoogle Scholar
  63. Holmes, A. (2001). Autism treatments: Chelation of mercury. Retrieved November 2, 2005 from http://www.healing-arts.org/children/holmes.htm .
  64. Horvath, K., Stefanatos, G., Sokolski, K. N., Wachtel, R., Nabors, L., & Tildon, J. T. (1998). Improved social and language skills after secretin administration in patients with autistic spectrum disorders. Journal of the Association for Academic Minority Physicians, 9, 9–15.PubMedGoogle Scholar
  65. Hughes, J. R., & John, E. R. (1999). Conventional and quantitative electroencephalography in psychiatry. Journal of Neuropsychiatry and Clinical Neurosciences, 11, 190–208.PubMedGoogle Scholar
  66. Ibric, V. L., & Hudspeth, W. (2003, February). QEEG and Roshi use in autism post-toxic encephalopathy—a case study. Presented at the 11th Annual Winter Brain Conference, Palm Springs, CA.Google Scholar
  67. Jarusiewicz, B. (2002). Efficacy of neurofeedback for children in the autistic spectrum: A pilot study. Journal of Neurotherapy, 6(4), 39–49.Google Scholar
  68. Jasper, H. (1958). The ten-twenty electrode system of the International Federation. Electroencephalography and Clinical Neurophysiology, 10, 371–375.Google Scholar
  69. Jensen, P. S., et al. (2007). 3-Year follow-up of the NIMH MTA study. Journal of the American Academy of Child and Adolescent Psychiatry, 46(8), 989–1002.PubMedGoogle Scholar
  70. Jesner, O. S., Aref-Adib, M., & Coren, E. (2007). Risperidone for autism spectrum disorder. Cochrane Database of Systematic Reviews, 1(CD005040). Retrieved July 18, 2008, from Cochrane Database of Systematic Reviews database.Google Scholar
  71. Just, M. A., Cherkassy, V. L., Keller, T. A., & Minshew, N. J. (2004). Cortical activation and synchronization during sentence comprehension in high-functioning autism: Evidence of underconnectivity. Brain, 127, 1811–1821.PubMedGoogle Scholar
  72. Kirby, D. (2005). Evidence of harm: Mercury in vaccines and the autism epidemic: A medical controversy. New York: St. Martin’s Press.Google Scholar
  73. Knivsberg, A. M., Reichelt, K. L., Hoien, T., & Nodland, M. (2002). A randomized, controlled study of dietary intervention in autistic syndromes. Nutritional Neuroscience, 5, 251–261.PubMedGoogle Scholar
  74. Kouijzer, M. E. J., de Moor, J. M. H., Gerrits, B. J. L., Buitelaar, J. K., & van Schie, H. T. (2009a). Long-term effects of neurofeedback treatment in autism. Research in Autism Spectrum Disorders, 3(2), 496–501.Google Scholar
  75. Kouijzer, M. E. J., de Moor, J. M. H., Gerrits, B. J. L., Congedo, M., & van Schie, H. T. (2009b). Neurofeedback improves executive functioning in children with autism spectrum disorders. Research in Autism Spectrum Disorders, 3(1), 145–162.Google Scholar
  76. Laibow, R. (1999). Medical applications of neurofeedback. In J. R. Evans & A. Abarbanel (Eds.), Introduction to quantitative EEG and neurofeedback (pp. 83–102). San Diego, CA: Academic Press.Google Scholar
  77. LaVaque, T. J., Hammond, D. C., Trudeau, D., Monastra, V., Perry, J., Lehrer, P., et al. (2002). Template for developing guidelines for the evaluation of the clinical efficacy of psychophysiological evaluations. Applied Psychophysiology and Biofeedback, 27(4), 273–281.Google Scholar
  78. Limsila, P., Toomim, H., Kijvithee, J., Bunthong, W., Pookjinda, J., & Utairatanakit, D. (2004). Hemoencephalography (HEG): An additional treatment for autism. Retrieved August 7, 2006 from http://www.biocompresearch.org/Thai_autism_study.htm.
  79. Linden, M. (2004, August). Case studies of QEEG mapping and neurofeedback with autism. Presented at the 12th Annual Conference of the International Society for Neuronal Regulation, Fort Lauderdale, FL.Google Scholar
  80. Linden, M., Habib, T., & Radojevic, V. (1996). A controlled study of the effects of EEG biofeedback on cognition and behavior of children with attention deficit disorder and learning disabilities. Biofeedback and Self-Regulation, 21, 35–50.PubMedGoogle Scholar
  81. Lord, C., Rutter, M., DiLavore, P. C., & Risi, S. (1999). Autism diagnostic observation schedule-WPS (ADOS-WPS). Los Angeles, CA: Western Psychological Services.Google Scholar
  82. Lovaas, O. I. (1987). Behavioral treatment and normal educational and intellectual functioning in young autistic children. Journal of Consulting and Clinical Psychology, 55, 3–9.PubMedGoogle Scholar
  83. Lovaas, O. I., Koegel, R., Simmons, J. Q., & Long, J. S. (1973). Some generalization and follow-up measures on autistic children in behavior therapy. Journal of Applied Behavior Analysis, 6(1), 131–165.PubMedGoogle Scholar
  84. Lubar, J. F. (1995). Neurofeedback for the management of attention-deficit/hyperactivity disorders. In M. S. Schwartz (Ed.), Biofeedback: A practitioner’s guide (3rd ed., pp. 493–522). New York: Guilford.Google Scholar
  85. Lubar, J. F. (1997). Neurobiological foundation for neurofeedback treatment of attention deficit hyperactivity disorder (ADD/HD). Biofeedback, 25(10), 4–23.Google Scholar
  86. Lubar, J. F., & Bahler, W. W. (1976). Behavioral management of epileptic seizures following EEG biofeedback training of the sensorimotor rhythm. Biofeedback and Self-Regulation, 7, 77–104.Google Scholar
  87. Lubar, J. F., Swartwood, M. O., Swartwood, J. N., & O’Donnell, P. H. (1995). Evaluation of the effectiveness of EEG training for ADHD in a clinical setting as measured by TOVA scores, behavioral ratings, and WISC-R performance. Biofeedback and Self-Regulation, 20, 83–99.PubMedGoogle Scholar
  88. Madsen, K. M., Lauritsen, M. B., Pedersen, C. B., Thorsen, P., Plesner, A., Andersen, P. H., et al. (2003). Thimerosal and the occurrence of autism: Negative ecological evidence from Danish population-based data. Pediatrics, 112, 604–606.PubMedGoogle Scholar
  89. Martin, A., Koenig, K., Anderson, G., & Scahill, L. (2003). Low dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of Autism and Developmental Disorders, 33(1), 77–85.PubMedGoogle Scholar
  90. Martin, A., Scahill, L., Klin, A., & Volkmar, F. R. (1999). Higher functioning pervasive developmental disorders: Rates and patterns of psychotropic drug use. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 923–931.PubMedGoogle Scholar
  91. McAlonan, G. M., Cheung, V., Cheung, C., Suckling, J., Lam, G. Y., Tai, K. S., et al. (2004). Mapping the brain in autism: A voxel-based MRI study of volumetric differences and intercorrelations in autism. Brain, 128(Pt 2), 268–276.PubMedGoogle Scholar
  92. McCandless, J. (2005). Children with starving brains: A medical treatment guide for autism spectrum disorder. Putney, VT: Bramble Books.Google Scholar
  93. McDougle, C. J., Brodkin, E. S., Naylor, S. T., Carlson, D. C., Cohen, D. J., & Price, L. H. (1998). Sertraline in adults with pervasive developmental disorders: A prospective, open-label investigation. Journal of Clinical Psychopharmacology, 18, 62–66.PubMedGoogle Scholar
  94. McDougle, C. J., Kresch, L. E., Goodman, W. K., Naylor, S. T., Volkmar, F. R., Cohen, D. J., et al. (1995). A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive–compulsive disorder. American Journal of Psychiatry, 152, 772–777.PubMedGoogle Scholar
  95. McDougle, C. J., Kresch, L. E., & Posey, D. J. (2000). Repetitive thoughts and behavior in pervasive developmental disorders: Treatment with serotonin reuptake inhibitors. Journal of Autism and Developmental Disorders, 30, 427–435.PubMedGoogle Scholar
  96. McDougle, C. J., Naylor, S. T., Cohen, D. J., Volkmar, F. R., Heninger, G. R., & Price, L. H. (1996). A double-blind, placebo controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53, 1001–1008.PubMedGoogle Scholar
  97. McEachin, J. J., Smith, T., & Lovaas, O. I. (1993). Long-term outcome for children with autism who received early intensive behavioral treatment. American Journal of Mental Retardation, 97, 359–372.PubMedGoogle Scholar
  98. Monastra, V. J., Lynn, S., Linden, M., Lubar, J. F., Gruzelier, J., & LaVaque, T. J. (2005). Electroencephalographic biofeedback in the treatment of attention-deficit/hyperactivity disorder. Applied Psychophysiology and Biofeedback, 30, 95–114.PubMedGoogle Scholar
  99. Monastra, V. J., Monastra, D. M., & George, S. (2002). The effects of stimulant therapy, EEG biofeedback, and parenting style on the primary symptoms of attention-deficit/hyperactivity disorder. Applied Psychophysiology and Biofeedback, 27, 231–249.PubMedGoogle Scholar
  100. Montgomery, D., Goldberg, J., Amar, M., Lacroix, V., Lecomte, J., Venasse, M., et al. (1999). Effects of hyperbaric oxygen therapy on children with spastic diplegic cerebral palsy: A pilot project. Undersea and Hyperbaric Medicine, 26, 235–242.PubMedGoogle Scholar
  101. Mountz, J. M., Tolbert, L. C., Lill, D. W., Katholi, C. R., & Liu, H. G. (1995). Functional deficits in autistic disorder: Characterization by technetium-99 m-HMPAO and SPECT. Journal of Nuclear Medicine, 36, 1156–1162.PubMedGoogle Scholar
  102. Mundy, P. (1993). Normal versus high-functioning status in children with autism. American Journal on Mental Retardation, 97, 381–384.Google Scholar
  103. Nakano, K., Noda, N., Tachikawa, E., Urano, M., Takazawa, M., Nakayama, T., et al. (2005). A preliminary study of methylcobalamin therapy in autism. Journal of Tokyo Women’s Medical Unversity, 75(3/4), 64–69.Google Scholar
  104. Namerow, L. B., Thomas, P., Bostic, J. Q., Prince, J., & Monuteaux, M. C. (2003). Use of citalopram in pervasive developmental disorders. Journal of Developmental and Behavioral Pediatrics, 24(2), 104–108.PubMedGoogle Scholar
  105. National Institute of Child Health and Human Development. (1999, December 8). [National Institutes of Health News Alert]. Study shows secretin fails to benefit children with autism. Retrieved August 6, 2007, from http://www.nichd.nih.gov/news/releases/secretin.cfm.
  106. National Institute of Mental Health. (2006). Autism spectrum disorders (pervasive developmental disorders). Retrieved June 7, 2006 from http://www.nimh.nih.gov/publicat/autism.cfm.
  107. Neubrander, J. A. (2005, May). Methyl-B12: Making it work for you! Presented at the Autism One Conference, Chicago, IL.Google Scholar
  108. Nighoghossian, N., Trouillas, P., Adeleine, P., & Salord, F. (1995). Hyperbaric oxygen in the treatment of acute ischemic stroke. Stroke, 26, 1369–1372.PubMedGoogle Scholar
  109. Oberman, L. M., Hubbard, E. M., McCleery, J. P., Altschuler, E. L., Ramachandran, V. S., & Pineda, J. A. (2005). EEG evidence for mirror neuron dysfunction in autism spectrum disorders. Cognitive Brain Research, 24, 190–198.PubMedGoogle Scholar
  110. Ohnishi, T., Matsuda, H., Hashimoto, T., Kunihiro, T., Nishikawa, M., Uema, T., et al. (2000). Abnormal regional cerebral blood flow in childhood autism. Brain, 123, 1838–1844.PubMedGoogle Scholar
  111. Othmer, S. (1997). Assessment. EEG spectrum biofeedback training manual. Encino, CA: EEG Spectrum, Inc.Google Scholar
  112. Owley, T., Walton, L., Salt, J., Guter, S. J., Winnega, M., Leventhal, B. L., et al. (2005). An open-label trial of escitalopram in pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 343–348.PubMedGoogle Scholar
  113. Ozonoff, S., & Cathcart, K. (1998). Effectiveness of a home program intervention for young children with autism. Journal of Autism and Developmental Disorders, 28, 25–32.PubMedGoogle Scholar
  114. Paolo, M., Viti, M. G., Montouri, M., LaVecchia, A., Cipolletta, E., Calvani, L., et al. (1998). The gluten-free diet: A nutritional risk factor for adolescents with celiac disease? Journal of Pediatric Gastroenterology and Nutrition, 27, 519–523.Google Scholar
  115. Pelphrey, K., Adolphs, R., & Morris, J. P. (2004). Neuroanatomical substrates of social cognition dysfunction in autism. Mental Retardation and Developmental Disabilities Research Reviews, 10, 259–271.PubMedGoogle Scholar
  116. Pineda, J. A., et al. (2008). Positive behavioral and electrophysiological changes following neurofeedback training in children with autism. Research in Autism Spectrum Disorders, 2(3), 557–581.Google Scholar
  117. Posey, D. J., Litwiller, M., Koburn, A., & McDougle, C. J. (1999). Paroxetine in autism. Journal of the American Academy of Child and Adolescent Psychiatry, 38(2), 111–112.PubMedGoogle Scholar
  118. Rangaswamy, M., Porjesz, B., Chorlian, D. B., Wang, K., Jones, K. A., Bauer, L. O., et al. (2002). Beta power in the EEG of alcoholics. Biological Psychiatry, 52, 831–842.PubMedGoogle Scholar
  119. Reichelt, K. (2001, October). Opioid peptides. Paper presented at the Defeat Autism Now Conference, San Diego, California.Google Scholar
  120. Reichelt, K., & Knivsberg, A. M. (2003, October). Why use the gluten-free and casein-free diet in autism and what the results have shown so far: Peptides and autism. Paper presented at the Defeat Autism Now Conference, Portland, Oregon.Google Scholar
  121. Research Units on Pediatric Psychopharmacology Autism Network. (2005a). Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry, 162, 1361–1369.Google Scholar
  122. Research Units on Pediatric Psychopharmacology Autism Network. (2005b). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Archives of General Psychiatry, 62(11), 1266–1274.Google Scholar
  123. Rimland, B., & Edelson, S. M. (2000). Autism treatment evaluation checklist (ATEC). Retrieved October 5, 2005 from http://autismeval.com/ari-atec/report1.html.
  124. Rippon, G., Brock, J., Brown, C., & Boucher, J. (2007). Disordered connectivity in the autistic brain: Challenges for the ‘new psychophysiology’. International Journal of Psychophysiology, 63(2), 164–172.PubMedGoogle Scholar
  125. Roberts, W., Weaver, L., Brian, J., Bryson, S., Emelianova, S., Griffiths, A. M., et al. (2001). Repeated doses of porcine secretin in the treatment of autism: A randomized, placebo-controlled trial. Pediatrics, 107(5), 71–80.Google Scholar
  126. Ross, J., & Caunt, J. (2003, September). A comparison of QEEG characteristics in pediatric Asperger’s syndrome and attention deficit disorder. Paper presented at the 11th Annual Conference of the International Society of Neuronal Regulation, Houston, TX.Google Scholar
  127. Rossignol, D. A., & Rossignol, L. W. (2006). Hyperbaric oxygen therapy may improve symptoms in autistic children. Medical Hypotheses, 67, 216–228.PubMedGoogle Scholar
  128. Rossignol, D. A., Rossignol, L. W., James, S. J., Melnyk, S., & Mumper, E. (2007). The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptom sin children with autism: An open-label pilot study. BMC Pediatrics, 7, 36–49.PubMedGoogle Scholar
  129. Rutter, M., LeCouteur, A., & Lord, C. (2003). Autism diagnostic interview-revised. Los Angeles, CA: Western Psychological Services.Google Scholar
  130. Sallows, G. O., & Graupner, T. D. (2005). Behavioral treatment for children with autism: Four-year outcome and predictors. American Journal of Mental Retardation, 110(6), 417–438.PubMedGoogle Scholar
  131. Sandler, A. D., Sutton, K. A., DeWeese, J., Girardi, M. A., Sheppard, V., & Bodfish, J. W. (1999). Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. New England Journal of Medicine, 341, 1801–1806.PubMedGoogle Scholar
  132. Santangelo, S. L., & Tsatsanis, K. (2005). What is known about autism: Genes, brain, and behavior. American Journal of Pharmacogenomics, 5(2), 71–92.PubMedGoogle Scholar
  133. Schmitz, N., Rubia, K., Daly, E., Smith, A., Williams, S., & Murphy, D. G. (2006). Neural correlates of executive function in autistic spectrum disorders. Biological Psychiatry, 59(1), 7–16.PubMedGoogle Scholar
  134. Schopler, E., & Reichler, R. J. (1971). Parents as cotherapists in the treatment of psychotic children. Journal of Autism and Childhood Schizophrenia, 1, 87–102.PubMedGoogle Scholar
  135. Schopler, E., Reichler, R. J., Bashford, A., Lansing, M. D., & Marcus, L. M. (1990). Individualized assessment and treatment for autistic and developmentally disables children (vol. 1): Psychoeducational profile revised. Austin, TX: PRO-ED.Google Scholar
  136. Schopler, E., Reichler, R. J., DeVellis, R. F., & Daly, K. (1980). Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). Journal of Autism and Developmental Disorders, 10(1), 91–103.PubMedGoogle Scholar
  137. Schopler, E., Short, A., & Mesibov, G. (1989). Relation of behavioral treatment to “normal functioning”: Comments on Lovaas. Journal of Consulting and Clinical Psychology, 57, 162–164.PubMedGoogle Scholar
  138. Scolnick, B. (2005). Effects of electroencephalogram biofeedback with Asperger’s syndrome. International Journal of Rehabilitation Research, 28(2), 159–163.PubMedGoogle Scholar
  139. Sheinkopf, S., & Siegel, B. (1998). Home-based behavioral treatment of young children with autism. Journal of Autism and Developmental Disorders, 28, 15–23.PubMedGoogle Scholar
  140. Sichel, A. G., Fehmi, L. G., & Goldstein, D. M. (1995). Positive outcome with neurofeedback treatment in a case of mild autism. Journal of Neurotherapy, 1(1), 60–64.Google Scholar
  141. Sicile-Kira, C. (2004). Autism spectrum disorders: The complete guide to understanding autism, Asperger’s syndrome, pervasive developmental disorder, and ASDs. New York: The Berkley Publishing Group.Google Scholar
  142. Siegel, B. (1996). The world of the autistic child: Understanding and treating autistic spectrum disorders. New York: Oxford University Press.Google Scholar
  143. Sinha, Y., Silove, N., & Williams, K. (2006). Chelation therapy and autism. British Medical Journal, 333(7571), 756.PubMedGoogle Scholar
  144. Smith, T., Groen, A. D., & Wynn, J. W. (2000). Randomized trial of intensive early intervention for children with pervasive developmental disorder. American Journal on Mental Retardation, 105, 269–285.PubMedGoogle Scholar
  145. Snead, R. W., Boon, F., & Presberg, J. (1994). Paroxetine for self-injurious behavior. Journal of the American Academy of Child and Adolescent Psychiatry, 33(6), 909–910.PubMedGoogle Scholar
  146. Starkstein, S. E., Vazquez, S., Vrancic, D., Nanclares, V., Manes, F., Piven, J., et al. (2000). SPECT findings in mentally retarded autistic individuals. Journal of Neuropsychiatry and Clinical Neurosciences, 12, 370–375.PubMedGoogle Scholar
  147. Steingard, R. J., Zimnitzky, B., DeMaso, D. R., Bauman, M. L., & Bucci, J. P. (1997). Sertraline treatment of transition associated anxiety and agitation in children with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 7(1), 9–15.PubMedGoogle Scholar
  148. Sterman, M. B., & Friar, L. (1972). Suppression of seizures in an epileptic following sensorimotor EEG feedback training. Journal of Electroencephalography and Clinical Neurophysiology, 33, 89–95.Google Scholar
  149. Stigler, K. A., Posey, D. J., & McDougle, C. J. (2004). Case report: Aripiprazole for maladaptive behavior in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 14(3), 455–463.PubMedGoogle Scholar
  150. Stoller, K. P. (2005). Quantification of neurocognitive changes before, during, and after hyperbaric oxygen therapy in a case of fetal alcohol syndrome. Pediatrics, 116(4), e586–e591.PubMedGoogle Scholar
  151. Stratton, K., Gable, G., & McCormick, M. C. (Eds.). (2001). Immunization safety review: Thimerosal containing vaccines and neurodevelopmental disorders. Washington, DC: National Academy Press.Google Scholar
  152. Tansey, M. A. (1993). Ten-year stability study of EEG biofeedback results for a hyperactive boy who failed a fourth grade perceptually impaired class. Biofeedback and Self-Regulation, 18(1), 33–44.PubMedGoogle Scholar
  153. Thompson, L., & Thompson, M. (1995, May). Autism/Asperger’s/obnoxious child, 3 case histories: How we get positive results with complex ADD clients. Paper presented at the Annual Conference of the Society for Neuronal Regulation, Scottsdale, AZ.Google Scholar
  154. Thompson, L., & Thompson, M. (2003a). Neurofeedback treatment for autistic spectrum disorders: Review of 60 cases-principles and outcome. Citation paper presented at the 34th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, Jacksonville, FL.Google Scholar
  155. Thompson, M., & Thompson, L. (2003b). The neurofeedback book: An introduction to basic concepts in applied psychophysiology. Wheat Ridge, CO: Association for Applied Psychophysiology and Biofeedback.Google Scholar
  156. Thompson, L., & Thompson, M. (2007, February). Autistic spectrum disorders, especially Asperger’s syndrome. Oral paper presented at the 38th Annual Meeting of the Association for Applied Psychophysiology and Biofeedback, Monterey, CA.Google Scholar
  157. Toomim, H., Mize, W., Kwong, P. C., Toomim, M., Marsh, R., Koslowski, G. P., et al. (2004). Intentional increase of cerebral blood oxygenation (HEG): An efficient brain exercise therapy. Journal of Neurotherapy, 8(3), 5–21.Google Scholar
  158. Troost, P. W., Lahuis, B. E., Steenhuis, M. P., Ketelaars, C. E., Buitelaar, J. K., van Engeland, H., et al. (2005). Long-term effects of risperidone in children with autism spectrum disorders: A placebo discontinuation study. Journal of the American Academy of Child & Adolescent Psychiatry, 44(11), 1137–1144.Google Scholar
  159. Vancassel, S., Durand, G., Barthelemy, C., Lejeune, B., Martineau, J., Guilloteau, D., et al. (2001). Plasma fatty acid levels in autistic children. Prostaglandins, Leukotrienes and Essential Fatty Acids, 65(1), 1–7.Google Scholar
  160. Verstraeten, T., Davis, R. L., DeStefano, F., Lieu, T. A., Rhodes, P. H., Black, S. B., et al. (2004). Safety of thimerosal-containing vaccines: A two-phased study of computerized health maintenance organization databases. Pediatrics, 112, 1039–1048.Google Scholar
  161. Wainright, P. E. (2002). Dietary essential fatty acids and brain function: A developmental perspective on mechanisms. The Proceedings of the Nutrition Society, 61, 61–69.Google Scholar
  162. Wechsler, D. (1989). Wechsler preschool and primary scale of intelligence-revised. San Antonio, TX: Psychological Corp.Google Scholar
  163. Welchew, D. E., Ashwin, C., Berkouk, K., Salvador, R., Suckling, J., Baron-Cohen, S., et al. (2005). Functional disconnectivity of the medial temporal lobe in Asperger’s syndrome. Biological Psychiatry, 57, 991–998.PubMedGoogle Scholar
  164. Yucha, C., & Montgomery, D. (2008). Evidence-based practice in biofeedback and neurofeedback. Wheat Ridge, CO: Association for Applied Psychophysiology and Biofeedback.Google Scholar
  165. Zilbovicius, M., Boddaert, N., Belin, P., Poline, J. B., Remy, P., Mangin, J. F., et al. (2000). Temporal lobe dysfunction in childhood autism: A PET study. American Journal of Psychiatry, 157, 1988–1993.PubMedGoogle Scholar
  166. Zuddas, A., Di Martino, A., Muglia, P., & Cichetti, C. (2000). Long-term risperidone for pervasive developmental disorder: Efficacy, tolerability, and discontinuation. Journal of Child and Adolescent Psychopharmacology, 10, 79–90.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Robert Coben
    • 1
  • Michael Linden
    • 2
  • Thomas E. Myers
    • 1
    • 3
  1. 1.Neurorehabilitation & Neuropsychological ServicesMassapequa ParkUSA
  2. 2.The Original ADD Treatment CentersSan Juan CapistranoUSA
  3. 3.Graduate Center of the City University of New YorkClinical Neuropsychology Subprogram at Queens CollegeQueensUSA

Personalised recommendations